Stelara ‘At The End Of Its Life’ As Biosimilars Put Pressure On J&J
After More Than A Decade Of Growth, Stelara Sales Declined By 6.6% In Q3 2024
With marketed European biosimilar rivals already making a dent in Stelara’s sales performance, Johnson & Johnson mourns its blockbuster’s upcoming loss of exclusivity across the Atlantic Ocean.
